ChemicalBook
Chinese Japanese Germany Korea

Etomidate

General anesthetics Uses
Etomidate
Etomidate structure
CAS No.
33125-97-2
Chemical Name:
Etomidate
Synonyms
R16659;R-1665;AMIDATE;Etomidat;PROPISCIN;ETOMIDATE;RADENARCON;D-ETOMIDATE;HYPNOMIDATE;Etomidate>
CBNumber:
CB4113298
Molecular Formula:
C14H16N2O2
Formula Weight:
244.29
MOL File:
33125-97-2.mol

Etomidate Properties

Melting point:
72-74°C
alpha 
D20 +66° (c = 1 in ethanol)
Boiling point:
160-162 °C(Press: 1 Torr)
Density 
1.11±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO: >10 mg/mL
form 
powder
pka
pKa 4.24(H2O t=25.0) (Uncertain)
color 
white
Merck 
14,3881
CAS DataBase Reference
33125-97-2(CAS DataBase Reference)
FDA UNII
Z22628B598
NIST Chemistry Reference
Etomidate(33125-97-2)
SAFETY
  • Risk and Safety Statements
Symbol(GHS) 
GHS07,GHS09
Signal word  Warning
Hazard statements  H410-H302-H400
Precautionary statements  P264-P270-P391-P501-P301+P312+P330-P273
Hazard Codes  Xn
Risk Statements  22
Safety Statements  36
RIDADR  UN 3077 9 / PGIII
WGK Germany  3
RTECS  NI4021500
HazardClass  9
PackingGroup  III
HS Code  29332900
Toxicity LD50 in mice, rats (mg/kg): 29.5, 14.8-24.3 i.v. (Janssen)

Etomidate price More Price(7)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich E6530 Etomidate >98% (HPLC), powder 33125-97-2 10mg $150 2021-03-22 Buy
Sigma-Aldrich 1268750 Etomidate United States Pharmacopeia (USP) Reference Standard 33125-97-2 200mg $366 2021-03-22 Buy
TCI Chemical E0897 Etomidate >98.0%(GC) 33125-97-2 100mg $83 2021-03-22 Buy
TCI Chemical E0897 Etomidate >98.0%(GC) 33125-97-2 500mg $247 2021-03-22 Buy
Cayman Chemical 21993 Etomidate ≥98% 33125-97-2 5mg $88 2021-03-22 Buy

Etomidate Chemical Properties,Uses,Production

General anesthetics

Etomidate is an ultra-short effect non-barbiturate intravenous anesthetic agent allowed to be used in China , it belongs to imidazole derivatives, the appearance is white crystalline powder, melting point 115 ℃, easily soluble in water, methanol, ethanol and propylene glycol, soluble in chloroform, insoluble in acetone, insoluble in ether. Its effects on the central nervous system is similar to barbiturates. Hypnotic effect of Etomidate is strong , and its efficacy is about 12 times higher than thiopental, it has no analgesic effect. It has a rapid onset of anesthesia, after 20 seconds of intravenous injection, it produces anesthesia, anesthesia is maintained for about 5 minutes, it is quick to wake up , increasing the dose will increase the duration of action accordingly. Compared with thiopental ,its anesthesia strength is larger and it has smaller effects on the respiratory and circulatory systems. It is suitable for induction of anesthesia. Intravenous anesthesia, can increase 19% of coronary blood flow and resistance is reduced by 19%. Its obvious advantage is having no negative impact on the cardiovascular system, and it has low toxicity,it has little effect on the respiratory and circulatory system, there is a brief respiratory depression,which makes systolic blood pressure decrease slightly, and make heart rate slightly faster, compared with thiopental, above effects are less, and it has no histamine release effect. It may affect the liver and kidney function and reduce brain oxygen consumption, reduce cerebral blood flow and intracranial pressure. Clinical generally use amount is 0.1~0.4mg/kg, natural wake is 7 to 14 minutes. Distribution half-life is 2.8 minutes, and elimination half-life is 160 minutes. Hydrolyze in the liver and plasma , and the vast majority of metabolites are excreted by the kidneys. The main disadvantages of etomidate is the inhibition of adrenal cortex function, especially after long-term medication.
Induction of anesthesia: quiet, comfortable, heart rate, blood pressure are stable. The usual dose is 0.2~0.3mg/kg. Elderly, frail or critically ill patients can be reduced to 0.1~0.15mg/kg, intravenous drip.It is more suitable for cardiovascular disease, poor cardiac reserve and critically ill patients. Maintenance of intravenous anesthesia or inhalation anesthesia in short surgery or short time heart surgery : intravenous, 0.1~0.2mg/(kg · h). Outpatient minor surgery or special tests: intravenous injection, 0.2~0.3mg/kg.
After the use of the product, there will be clonic muscle contraction, using droperidol or fentanyl before anesthesia can reduce the incidence of myoclonus; if etomidate is used as inducing halothane anesthesia, the amount of halothane should be reduced .
The above information is edited by the chemicalbook of Tian Ye.

Uses

Short-time intravenous anesthetics.

Chemical Properties

Colourless solid

Originator

Hypnomidate,Janssen,W. Germany,1977

Uses

antiestrogen

Uses

Etomidate is a hypnotic.

Uses

A GABAA receptors agonist.

Definition

ChEBI: The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.

Manufacturing Process

To a mixture of 1,115 parts dl-1-phenylethylamine and 950 parts dimethylformamide are added successively 655 parts triethylamine and 1,130 parts ethyl chloroacetate. After the addition is complete, the whole is stirred overnight. Then there are added 5,600 parts anhydrous ether and the whole is filtered.
The filtrate is washed four times with water, dried and evaporated, yielding dl- N-[(ethoxycarbonyl)methyl] -1-phenylethylamine. This residue is dissolved in 4,800 parts xylene while refluxing and to this solution are added 450 parts formic acid. After boiling for a few hours, the mixture is cooled and washed successively three times with a 20% solution of formic acid, water, sodium hydrogen carbonate solution.
The organic layer is then dried, filtered and evaporated. The oily residue is distilled in vacuo, yielding 1,600 parts dl-N-formyl-N- [(ethoxycarbonyl)methyl]-1-phenylethylamine (boiling point 160°C to 170°C at 0.8 mm pressure). 30 parts of a sodium dispersion, 50% in paraffin oil are added to 450 parts tetrahydrofuran and the whole is slowly heated to a temperature of 40°C, while stirring. While maintaining this temperature (cooling on a water bath is necessary) there are added portionwise 30 parts ethanol.
After the addition is complete, the whole is cooled on an ice bath and there is added dropwise a solution of 144 parts dl-N-formyl-N- [(ethoxycarbonyl)methyl]-1-phenylethylamine in 133 parts ethyl formate. After the addition is complete, the mixture is stirred overnight at room temperature.
Then there are added 160 parts ether. After stirring for 5 minutes the mixture is poured into 1,500 parts water. The aqueous layer is separated, washed twice with 80 parts diisopropyl ether and then there are added successively 114 parts concentrated hydrochloric acid and 90 parts potassium thiocyanate in 200 parts water. The mixture is stirred for 24 hours, where upon an oil is separated.
After the addition of 750 parts water, a crystalline product is precipitated. The mixture is further stirred overnight. The solid is then filtered off and recrystallized from a mixture of ethanol and water (1:1 by volume) to yield dl- 1-(phenylethyl)-2-mercapto-5-(ethoxycarbonyl)imidazole; its melting point is 129.8°C to 130.8°C.
To a stirred mixture of 140 parts nitric acid (d = 1.37), 1 part sodium nitrate and 240 parts water are added portionwise 89 parts dl-1-(1-phenylethyl)-2- mercapto-5-(ethoxycarbonyl)imidazole. After the addition is complete, the whole is stirred for 2 hours at room temperature. The free base is liberated by addition of solid sodium carbonate and the whole is extracted with 120 parts anhydrous ether while heating. The aqueous layer is separated and extracted twice with 80 parts anhydrous ether.
The combined extracts are dried over magnesium sulfate, filtered and to the filtrate is added 2-propanol previously saturated with gaseous hydrogen chloride. The precipitated salt is filtered off, dried for 2 days at 60°C, to yield dl-1-(1-phenylethyl)-5-(ethoxycarbonyl)imidazole hydrochloride. It has a melting point 142°C to 142.8°C.

brand name

Amidate (Hospira);Hypnomidate concentrate;Hypnomidate injection;Hypromidate;Nalgol;Sibu.

Therapeutic Function

Hypnotic

World Health Organization (WHO)

Etomidate, a potent hypnotic agent, was introduced in 1977 for use as an intravenous anaesthetic. Its prolonged use can inhibit adrenal steroidogenesis and, following reports of reduced serum cortisol levels unresponsive to ACTH injection, the manufacturer suspended promotion of etomidate for sedation in intensive care in 1983. In 1985 regulatory action taken only in the United Kingdom further restricted use of the drug to induction of anaesthesia. Etomidate remains widely available and is currently registered for induction of anaesthesia in 34 countries and for maintenance of anaesthesia in 17 countries. It has never been registered for sedation.

Biological Functions

The pharmacological properties of etomidate (Amidate) are similar to those of the barbiturates, although its use may provide a greater margin of safety because of its limited effects on the cardiovascular and respiratory systems. Since it has a relatively short elimination halflife (t1/2β = 2.9 hours), in addition to its use as an induction agent, etomidate has been used as a supplement to maintain anesthesia in some critically ill patients. Etomidate is rapidly hydrolyzed in the liver.

General Description

Etomidate is a carboxylated imidazole intended for the inductionof general anesthesia. It is marketed as the morepotent R (+) isomer. It is believed to exert its anestheticeffect via positive modulation of the GABAA receptor. Itis not water soluble and is available in the United States as a2-mg/mL solution containing 35% v/v propylene glycol andin Europe as a soybean oil and medium-chain triglyceridesformulation. The propylene glycol has been associatedwith moderate-to-severe pain on injection and irritation ofthe vascular tissue. A high incidence of skeletal musclemovements were noted in about 32% of patients followingetomidate injection. Case reports of seizures are also foundin the literature.

Biological Activity

General anesthetic with GABA modulatory and GABA-mimetic actions; selectively interacts with β 2- and β 3-subunit containing GABA A receptors. Short acting and potent hypnotic, with low toxicity.

Clinical Use

Etomidate should only beused for induction of anesthesia when the cardiac benefitsoutweigh the risks associated with adrenal insufficiency.Etomidate is quickly distributed throughout most organsin the body after intravenous administration and the tissueconcentrations equal and sometimes exceed the plasmaconcentrations. The lipid solubility of the drug allows it torapidly penetrate into the brain with peak concentrationsoccurring within 1 minute of administration. Etomidate israpidly metabolized in the plasma and liver via esterases.About 75% of the drug is eliminated in the urine as the inactiveester hydrolyzed carboxylic acid.

Side effects

Etomidate may cause pain on injection and may produce myoclonic muscle movements in approximately 40% of patients during its use as an induction anesthetic. In addition, etomidate can suppress the adrenocortical response to stress, an effect that may last up to 10 hours.

Veterinary Drugs and Treatments

Etomidate may be useful as an alternative to thiopental or propofol for anesthetic induction in small animals, particularly in patients with preexisting cardiac dysfunction, head trauma, or that are critically ill.

Metabolism

Etomidate is hydrolyzed by hepatic esterases to the corresponding inactive carboxylic acid, with subsequent renal and biliary excretion terminating its action. Its apparent elimination half-life is approximately 5 to 6 hours, with a volume of distribution of 5 to 7 L/kg. Changes in hepatic blood flow or hepatic metabolism will have only moderate effects on etomidate disposition. Concerns regarding the ability of etomidate to precipitate myoclonic jerks and inhibit adrenal steroid synthesis have been reported.

Etomidate Preparation Products And Raw materials

Raw materials

Preparation Products


Etomidate Suppliers

Global( 250)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Hong Kong Tiansheng New Material Trading Co., Ltd
+8617320695765
17320695765 zxx@hktiansheng.com China 337 58
Henan DaKen Chemical CO.,LTD.
+86-371-66670886
info@dakenchem.com China 21032 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22607 55
Guangzhou PI PI Biotech Inc
+8618371201331
020-81716319 sales@pipitech.com;87478684@qq.com China 3245 55
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 26734 60
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 29961 58
GIHI CHEMICALS CO.,LIMITED
08657186217390
sales@gihichemicals.com CHINA 310 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 linda@hubeijusheng.com CHINA 28229 58
Hebei Guanlang Biotechnology Co., Ltd.
+8619930503282
sales3@crovellbio.com China 5450 58
Hubei xin bonus chemical co. LTD
86-13657291602
027-59338440 linda@hubeijusheng.com CHINA 23035 58

View Lastest Price from Etomidate manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-10-11 Etomidate
33125-97-2
US $5.50 / KG 1KG 99% 10kg Hong Kong Tiansheng New Material Trading Co., Ltd
2021-10-11 Etomidate
33125-97-2
US $5.50 / KG 1KG 99% 1KG Hong Kong Tiansheng New Material Trading Co., Ltd
2021-10-11 Etomidate
33125-97-2
US $100.00 / KG 1KG 99% 100KG Hong Kong Tiansheng New Material Trading Co., Ltd

33125-97-2(Etomidate)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved